AI Engines For more Details: Perplexity Kagi Labs You
Bronchodilation: Isoetharine mesylate salt acts as a beta-adrenergic agonist, specifically targeting beta-2 receptors in the smooth muscles of the bronchial airways. Activation of these receptors leads to relaxation of the bronchial smooth muscles, resulting in bronchodilation. This helps to widen the airways, making it easier for air to flow in and out of the lungs, and improving breathing in individuals with asthma or COPD.
Relief of Acute Bronchospasm: Isoetharine is often used to provide rapid relief of acute bronchospasm or acute exacerbations of asthma or COPD. Its fast onset of action makes it particularly useful for relieving sudden symptoms such as wheezing and shortness of breath during asthma attacks.
Prevention of Exercise-Induced Bronchoconstriction: Isoetharine may also be used prophylactically to prevent exercise-induced bronchoconstriction (EIB) in individuals with asthma. By opening up the airways before physical activity, it can help reduce the severity of symptoms triggered by exercise.
Management of Chronic Respiratory Conditions: In addition to providing immediate relief of bronchospasm, isoetharine may be used as part of the long-term management of chronic respiratory conditions like asthma or COPD. Regular use can help control symptoms and improve lung function over time, reducing the frequency and severity of exacerbations.
Adjunct Therapy: Isoetharine mesylate salt may be used in combination with other medications for asthma or COPD management, such as inhaled corticosteroids or long-acting beta agonists, to achieve better symptom control and improve overall respiratory function.
Nebulization: Isoetharine mesylate salt is commonly administered via inhalation using a nebulizer device, which converts the medication into a fine mist that can be inhaled into the lungs. This method allows for efficient delivery of the drug directly to the bronchial airways, maximizing its therapeutic effects.
Side Effects: While isoetharine mesylate salt is generally well-tolerated, it may cause side effects in some individuals. Common side effects may include tremors, nervousness, palpitations (rapid heartbeat), headache, dizziness, and nausea. These side effects are usually mild and transient.
Caution in Certain Populations: Isoetharine mesylate salt should be used with caution in individuals with pre-existing cardiovascular conditions such as hypertension, arrhythmias, or coronary artery disease, as it can potentially exacerbate these conditions. It should also be used cautiously in pregnant or breastfeeding women, and in children, with careful monitoring by a healthcare professional.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.5 | 0.2 |
| ADHD | 3.8 | 0.6 | 5.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.4 | 1.3 | 0.85 |
| Allergies | 5.1 | 2.9 | 0.76 |
| Allergy to milk products | 1.7 | 1.6 | 0.06 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 5.3 | 5.1 | 0.04 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.3 | 1.3 | 1.54 |
| Ankylosing spondylitis | 3.5 | 1.2 | 1.92 |
| Anorexia Nervosa | 1.2 | 2.5 | -1.08 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.3 | 0.67 |
| Asthma | 4.2 | 1.7 | 1.47 |
| Atherosclerosis | 2.3 | 1.1 | 1.09 |
| Atrial fibrillation | 3.5 | 2.1 | 0.67 |
| Autism | 6.4 | 7.1 | -0.11 |
| Autoimmune Disease | 0.9 | 0.8 | 0.13 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 1.9 | 1.4 | 0.36 |
| Brain Trauma | 0.6 | 1.4 | -1.33 |
| Breast Cancer | 1.1 | 0.3 | 2.67 |
| Cancer (General) | 0.9 | 1.8 | -1 |
| Carcinoma | 4.1 | 2.6 | 0.58 |
| Celiac Disease | 2 | 3.5 | -0.75 |
| Cerebral Palsy | 0.9 | 1.3 | -0.44 |
| Chronic Fatigue Syndrome | 3.3 | 3.6 | -0.09 |
| Chronic Kidney Disease | 3.2 | 2 | 0.6 |
| Chronic Lyme | 0 | 0.8 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.7 | -0.21 |
| Chronic Urticaria (Hives) | 1.4 | 0.5 | 1.8 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1 | 0.5 |
| Cognitive Function | 2.9 | 1.1 | 1.64 |
| Colorectal Cancer | 5.6 | 2.8 | 1 |
| Constipation | 2.2 | 1.2 | 0.83 |
| Coronary artery disease | 2 | 2.3 | -0.15 |
| COVID-19 | 5.5 | 5.3 | 0.04 |
| Crohn's Disease | 6.7 | 4.6 | 0.46 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 1.1 | 1.5 | -0.36 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 2.8 | 1.1 | 1.55 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 8.5 | 6.6 | 0.29 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 1.2 | 1.5 | -0.25 |
| Endometriosis | 3.1 | 2.5 | 0.24 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.7 | 1.2 | 1.25 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 2.1 | 2.4 | -0.14 |
| Functional constipation / chronic idiopathic constipation | 4.3 | 3.4 | 0.26 |
| gallstone disease (gsd) | 3.2 | 1.1 | 1.91 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.5 | 1.6 |
| Generalized anxiety disorder | 2.1 | 1.7 | 0.24 |
| Gout | 1.8 | 1.2 | 0.5 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.4 | 0.7 | -0.75 |
| Halitosis | 0.9 | 0.9 | |
| Hashimoto's thyroiditis | 3.3 | 1.3 | 1.54 |
| Heart Failure | 2.8 | 1.7 | 0.65 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1 | 0.6 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.8 | |
| hyperglycemia | 1.4 | 1.1 | 0.27 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.4 | 3.9 | -0.15 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 2.7 | 0.4 | 5.75 |
| IgA nephropathy (IgAN) | 1.3 | 2.2 | -0.69 |
| Inflammatory Bowel Disease | 4.3 | 5.6 | -0.3 |
| Insomnia | 1.9 | 2.1 | -0.11 |
| Intelligence | 1.4 | 0.1 | 13 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 5.2 | 3.8 | 0.37 |
| ischemic stroke | 2.5 | 1.7 | 0.47 |
| Liver Cirrhosis | 6.5 | 3.6 | 0.81 |
| Long COVID | 5.2 | 5.7 | -0.1 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.3 | 1 | 0.3 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 0.7 | 0.9 | -0.29 |
| ME/CFS with IBS | 0.6 | 1.4 | -1.33 |
| ME/CFS without IBS | 0 | 1.6 | 0 |
| Menopause | 0.7 | 0.5 | 0.4 |
| Metabolic Syndrome | 6.3 | 6.3 | 0 |
| Mood Disorders | 7.6 | 5.6 | 0.36 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.1 | 2 |
| Multiple Sclerosis | 3.8 | 3.4 | 0.12 |
| Multiple system atrophy (MSA) | 0.4 | 0.7 | -0.75 |
| myasthenia gravis | 0.6 | 0.5 | 0.2 |
| neuropathic pain | 2.4 | -2.4 | |
| Neuropathy (all types) | 0.1 | 1.9 | -18 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 3.3 | 0.33 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 7.6 | 5.7 | 0.33 |
| obsessive-compulsive disorder | 3.8 | 2.5 | 0.52 |
| Osteoarthritis | 1.4 | 0.9 | 0.56 |
| Osteoporosis | 2.1 | 1.3 | 0.62 |
| pancreatic cancer | 1.5 | 0.3 | 4 |
| Parkinson's Disease | 5.1 | 4.9 | 0.04 |
| Polycystic ovary syndrome | 4.3 | 2.2 | 0.95 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 0.9 | 0 |
| Primary sclerosing cholangitis | 1.7 | 1.6 | 0.06 |
| Psoriasis | 2.4 | 2 | 0.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.4 | 3.8 | 0.42 |
| Rosacea | 0.8 | 0.8 | 0 |
| Schizophrenia | 5.3 | 2.9 | 0.83 |
| scoliosis | 0.8 | 0.7 | 0.14 |
| Sjögren syndrome | 2.2 | 2.6 | -0.18 |
| Sleep Apnea | 2.2 | 1.6 | 0.38 |
| Slow gastric motility / Gastroparesis | 1.4 | 0.3 | 3.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 0.3 | 4.33 |
| Stress / posttraumatic stress disorder | 2.9 | 2.1 | 0.38 |
| Systemic Lupus Erythematosus | 3.3 | 1.8 | 0.83 |
| Tic Disorder | 0.9 | 1.3 | -0.44 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 3.7 | 2.9 | 0.28 |
| Type 2 Diabetes | 7.6 | 5.8 | 0.31 |
| Ulcerative colitis | 4.5 | 4.4 | 0.02 |
| Unhealthy Ageing | 3.6 | 2 | 0.8 |
| Vitiligo | 2 | 1.1 | 0.82 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]